CD19-TriCAR-T/SILK Cell Therapy(Timmune Biotech)

N/A

Report date: 2024/11/22 20:00:28

Base Information

Drug NameCD19-TriCAR-T/SILK Cell Therapy(Timmune Biotech)
Drug Alias Name三功能CD19-TriCAR-T细胞疗法CD19-TriCAR-T cellsCD19-TriCAR-SILK cell therapy三功能CD19-TriCAR-SILK细胞疗法CD19-TriCAR-T and CD19-TriCAR-SILK cell therapy
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, Non-HodgkinLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesTianjin Timmune Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTianjin Timmune Biotech Inc
Active IndicationsN/A
Inactive IndicationsLymphoma, Non-HodgkinLeukemia

Other Information

ATC CodeN/A
Related LinksN/A